论文部分内容阅读
目的 比较黄芪与氯沙坦对临床期糖尿病肾病的疗效。方法 将血糖、血压控制比较理想的 68例临床期糖尿病肾病患者随机分为氯沙坦组 2 4例、黄芪组 2 6例和糖尿病肾病组 18例 ,疗程 8周。结果 ⑴氯沙坦组治疗后 2 4h尿白蛋白、2 4h尿蛋白、尿 β2 -MG明显下降 (P均 <0 0 5 ) ,肾小球滤过率升高 (P <0 0 5 )。⑵黄芪能显著降低 2 4h尿白蛋白、2 4h尿蛋白、尿 β2 -MG(P均 <0 0 1) ,升高肾小球滤过率 (P <0 0 1) ,其效果明显强于氯沙坦 (P均 <0 0 5 )。⑶糖尿病肾病对照组 2 4h尿白蛋白、2 4h尿蛋白、尿 β2 -MG、肾小球滤过率则无明显变化 ( P 均 >0 0 5 )。结论 黄芪是治疗临床期糖尿病肾病比较有效的药物
Objective To compare the curative effect of astragalus and losartan on clinical diabetic nephropathy. Methods Sixty-eight patients with diabetic nephropathy whose blood glucose and blood pressure control were ideal were randomly divided into losartan group (24 cases), astragalus group (26 cases) and diabetic nephropathy group (18 cases) for 8 weeks. Results (1) Urinary albumin, 24 hours urinary protein and urinary β2-MG were significantly decreased in losartan group 24 hours after treatment (all P0 05), glomerular filtration rate (P0 05). ⑵ astragalus can significantly reduce 24 h urinary albumin, 24 h urinary protein, urinary β2-MG (P <0.01), increased glomerular filtration rate (P <0.01), the effect was significantly stronger than Losartan (all P <0 05). (3) Urine albumin, 24h urinary protein, urinary β2-MG, glomerular filtration rate in 24 h diabetic nephropathy control group had no significant change (all P> 0.05). Conclusion Astragalus is a more effective treatment of diabetic nephropathy in clinical medicine